Edition:
United States

Vertex Pharmaceuticals Inc (VRTX.OQ)

VRTX.OQ on NASDAQ Stock Exchange Global Select Market

89.98USD
24 Mar 2017
Change (% chg)

$0.93 (+1.04%)
Prev Close
$89.05
Open
$89.74
Day's High
$90.46
Day's Low
$89.14
Volume
385,943
Avg. Vol
617,568
52-wk High
$103.68
52-wk Low
$71.50

VRTX.OQ

Chart for VRTX.OQ

About

Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications. The... (more)

Overall

Beta: 0.78
Market Cap(Mil.): $22,354.46
Shares Outstanding(Mil.): 248.44
Dividend: --
Yield (%): --

Financials

  VRTX.OQ Industry Sector
P/E (TTM): -- 47.98 29.94
EPS (TTM): -0.46 -- --
ROI: -4.47 -2.56 13.01
ROE: -10.69 5.14 14.16

Vertex investor can proceed with records lawsuit - Mass. top court

Massachusetts's highest court on Monday revived a lawsuit by a shareholder of Vertex Pharmaceuticals Inc seeking access to corporate records to investigate whether the drugmaker's board breached its duties to investors.

Mar 20 2017

BRIEF-Vertex to acquire CTP-656 from Concert Pharmaceuticals

* Vertex to acquire CTP-656 from Concert Pharmaceuticals for the treatment of cystic fibrosis

Mar 06 2017

BRIEF-Vertex to acquire CTP-656 from Concert Pharmaceuticals

* Vertex to acquire CTP-656 from Concert Pharmaceuticals for the treatment of cystic fibrosis Source text for Eikon: Further company coverage:

Mar 06 2017

BRIEF-Vertex Pharmaceuticals Q4 earnings per share $0.13

* Vertex reports full-year and fourth-quarter 2016 financial results

Jan 25 2017

Vertex issues revenue outlook for cystic fibrosis treatments

Vertex Pharmaceuticals Inc said on Sunday that it expected full-year 2017 revenue from its Orkambi cystic fibrosis treatment of $1.1 billion to $1.3 billion and revenue from its Kalydeco treatment of $690 million to $710 million.

Jan 08 2017

Vertex Pharmaceuticals revenue outlook for cystic fibrosis treatments

Jan 8 Vertex Pharmaceuticals Inc said on Sunday that it expected full-year 2017 revenue from its Orkambi cystic fibrosis treatment of $1.1 billion to $1.3 billion and revenue from its Kalydeco treatment of $690 million to $710 million.

Jan 08 2017

BRIEF-Vertex Pharmaceuticals Q3 adj. earnings 16 cents/share

* Q3 earnings per share view $0.18 -- Thomson Reuters I/B/E/S

Oct 25 2016

BRIEF-Vertex says data from study of VX-152 expected in second half of 2017

* Announces planned initiation of phase 2 studies evaluating the next-generation correctors VX-440 and VX-152 in triple combination regimens to treat the underlying cause of cystic fibrosis

Oct 25 2016

BRIEF-Vertex Pharma: Amended and expanded agreement with Cystic Fibrosis Foundation Therapeutics

* Vertex Pharma - on oct 13 amended and expanded research, development and commercialization agreement with cystic fibrosis foundation therapeutics inc

Oct 14 2016

1st Circuit tosses securities lawsuit against Vertex

Vertex Pharmaceuticals does not have to face a shareholder lawsuit accusing it of overstating the benefits of an experimental drug treatment for cystic fibrosis, a federal appeals court has ruled.

Oct 07 2016

More From Around the Web

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $125.48 -0.42
Pfizer Inc. (PFE.N) $34.00 -0.29
Novartis AG (NOVN.S) CHF73.75 -0.40
Merck & Co., Inc. (MRK.N) $63.18 -0.10
Roche Holding Ltd. (ROG.S) CHF252.90 +0.30
Roche Holding Ltd. (RO.S) CHF252.50 0.00
Sanofi SA (SASY.PA) €82.87 -0.43
GlaxoSmithKline plc (GSK.L) 1,670.50 -4.50
AbbVie Inc (ABBV.N) $65.62 -0.03
Bristol-Myers Squibb Co (BMY.N) $55.89 +0.12

Earnings vs. Estimates